SCHEMBL30385016

SCHEMBL30385016

Clc1cccc(Cl)c1-c1nc2ccccc2[nH]1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 9/20 0.69
RAB9A P51151 9/20 0.69
KDM4E B2RXH2 9/20 0.69
ALDH1A1 P00352 9/20 0.69
GPR55 Q9Y2T6 1/20 0.69
SMN1; SMN2 Q16637 5/20 0.64
HSD17B10 Q99714 4/20 0.64
TP53 P04637 4/20 0.64
PKM P14618 3/20 0.64
NPSR1 Q6W5P4 2/20 0.64
ABCB11 O95342 1/20 0.64
GUSB P08236 1/20 0.61
GAA P10253 2/20 0.56
HPGD P15428 4/20 0.54
MAPT P10636 3/20 0.54
LMNA P02545 2/20 0.54
MEN1 O00255 1/20 0.54
KMT2A Q03164 1/20 0.54
NFKB1 P19838 1/20 0.53
HTT P42858 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19960365 0.89 NPC1 (0.73) NPC1RAB9AKDM4EALDH1A1GPR55
SCHEMBL19960368 0.86 NPC1 (0.76) NPC1RAB9AKDM4EALDH1A1GPR55
SCHEMBL19960367 0.85 RAB9A (0.79) NPC1RAB9AKDM4EALDH1A1GPR55
SCHEMBL19960380 0.82 NPC1 (0.56) NPC1RAB9AKDM4EALDH1A1GPR55
SCHEMBL29695905 0.81 NPC1 (1.00) NPC1RAB9AKDM4EALDH1A1GPR55
SCHEMBL162191 0.81 NPC1 (1.00) NPC1RAB9AKDM4EALDH1A1GPR55
SCHEMBL13406020 0.81 DGAT1 (0.54) NPC1RAB9AKDM4EALDH1A1GPR55
SCHEMBL7270947 0.80 JAK2 (0.51) NPC1RAB9AKDM4EALDH1A1GPR55
SCHEMBL172216 0.80 NPC1 (1.00) NPC1RAB9AKDM4EALDH1A1GPR55
SCHEMBL30561047 0.80 NPC1 (1.00) NPC1RAB9AKDM4EALDH1A1GPR55

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023084449-A1 DIAMINOCYCLOPENTYLPYRIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER NOVARTIS AG (CH) 2023-05-19 WO disclosed